We are proud to work collaboratively with a number of corporate partners to enable our community to live fulfilled lives today as well as supporting the pharmaceutical industry in their mission to develop potential new treatments. We are very grateful to the following corporate partners for all they do to support our work and our community.
Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has established a new focus on Retinal Diseases to develop transformational therapies and platforms that restore and preserve vision. This new focus expands Johnson & Johnson’s already broad ophthalmic footprint, and includes a pipeline of innovative treatments for inherited retinal diseases and more common retinal diseases affecting millions of people worldwide. Learn more at: https://www.janssen.com/cardiovascular-and-metabolism/retinal-disease
Novartis has supported Retina UK through project funding and event sponsorship. Novartis holds the European licence for the first ever commercially available gene therapy for an inherited retinal dystrophy – Luxturna – designed to treat sight loss caused by mutations on the RPE65 gene.
PROQR has supported Retina UK through project funding and event sponsorship. Their research and development pipeline includes pre-clinical and clinical trials relating to Leber congenital amaurosis (LCA) 10, Usher syndrome type 2a and autosomal dominant RP caused by a particular mutation in the rhodopsin (RHO) gene.
We’d love to hear from you if you are interested in working with us. We take a flexible and personalised approach to our relationships with corporate supporters – give Fiona a call on 01280 815900 or email fiona.leahy@RetinaUK.org.uk for an informal chat.